LAROTRECTINIB-NAVIGATE

NCT02122913, NCT02637687, NCT02576431 📎

Regimen

Experimental
Larotrectinib (selective pan-TRK inhibitor)
Control
single-arm basket (no control)

Population

NTRK fusion-positive solid tumors (tissue-agnostic), any line, TRK inhibitor naive; CRC subgroup reported separately.

Key finding

All tumor types (n=55, 17 different tumor types, 4 months to 76 years): ORR 75% (95% CI 61–85) by independent review; at 1 year 71% of responses ongoing; 55% progression-free; median duration of response and PFS not reached at 9.4 months follow-up; 86% of responders continuing treatment or underwent curative surgery; grade 3–4 drug-related AEs: none occurred in >5% of patients; no discontinuations.

Source: PMID 29466156

Timeline

    Guideline citations

    • NCCN Colon (p.36)
    • NCCN Rectal (p.46)